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 Abstract 
 With the growing availability of new health care technologies and rapidly emerging biomarker discoveries, clinicians need 
advice on the clinical validity and utility of new tests and whether they improve clinical, patient-centred, organizational or 
economic outcomes. High quality clinical practice guidelines (CPGs), based on well-designed and conducted test evalua-
tion studies, are tools for translating research into practice and in promoting a value- and evidence-based approach for 
clinical utilization and reimbursement of new biomarkers. Such study protocols should be appropriate for the questions 
addressed at each stage of biomarker development: 1/ Basic research into the association of disease with the new biomar-
ker; 2/ Modelling the potential use of the new biomarker in clinical practice; Studies on the 3/ analytic validity; 4/ clinical 
validity (effi cacy); 5/ clinical utility (effectiveness); and 6/ clinical impact (effi ciency) of testing. Irrespective of the facts that 
CPGs potentially infl uence important clinical decisions and thus patient outcomes, current approaches to CPG develop-
ment often do not follow the rigorous processes of scientifi c publications. Guidelines should be outcome oriented; reliable 
and free from any forms of bias; based on high quality research or on formal consensus when evidence is confl icting 
or lacking; multidisciplinary; fl exible and applicable to various clinical circumstances and patient preferences; clear; cost-
effective; appropriately disseminated and implemented; amenable to measurement of their impact in practice; and regularly 
reviewed and updated. Therefore until guideline-making and reporting standards are improved, all CPGs should be care-
fully scrutinized for methodological and content validity before being adopted, adapted and used in clinical practice. 
 Key Words:  biomarker ,  evidence-based laboratory medicine ,  guideline ,  translational medicine 
Abbreviations: ACCE: Analytic validity, Clinical validity, Clinical utility and Ethical, legal and social implications; AGREE: 
Appraisal of Guidelines for Research and Evaluation; CPG: Clinical Practice Guideline; RCT: Randomized Controlled Trial
 Introduction 
 Translational research, which aims to bridge the gap 
between the identifi cation of new biomarkers and 
proving that these are clinically effective and improve 
patient outcomes, is still in its infancy and faces two 
major obstacles. The fi rst is the translation of basic 
science discoveries into clinical studies; the second is 
to translate clinical proof-of-concept studies to evi-
dence-based personalized treatment guidelines or 
health policies [1]. With the growing availability of 
new biomarkers, clinicians need advice on their 
validity and utility. New laboratory biomarkers have 
clinical value only if they provide additional benefi t 
to patients at acceptable costs. Laboratory tests by 
themselves rarely infl uence patient-centred outcomes 
directly, and often they are disease-centred predic-
tors or surrogates to patient-relevant endpoints. 
However, tests initiate a cascade of decisions which 
subsequently determine the course and costs of 
patient management and thus indirectly contribute 
to patient-centred and economic outcomes. Recog-
nizing the importance of testing in medical decisions, 
on the background of limited health care resources, 
it is now widely promoted that clinical utilization and 
reimbursement of diagnostic tests should move from 
a cost-based, towards a value- and evidence-based 
approach. It is also commonly believed that high 
quality, evidence-based clinical practice guidelines 
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(CPGs) might be most suited in transmitting this 
message to practicing clinicians and their patients. 
 How to evaluate biomarkers before 
recommending them for practice? 
 Recommendations of using a new test or incorporating 
it into the patient management pathway should be 
preceded by and based upon specifi c test evaluation 
studies and technology appraisals. Test evaluation 
should be carried out in a step-wise fashion, with care-
fully planned study designs appropriate for the questions 
addressed at each stage of research (Figure 1). The 
rigour and depth of evaluation should be proportionate 
to the questions and expected outcomes being 
addressed. 
 Phase I: Basic research into the association of disease 
with the new biomarker 
 In the initial phases of biomarker discovery the key 
question is: Do patients with the target disorder have 
different test results from normal individuals? Case-
control studies are often suffi cient for answering 
these early stage questions. 
 Phase II: Modelling the potential use of the new 
biomarker in clinical practice 
 In the next phase careful consideration should be 
given to the purpose, the clinical context and path-
way of testing, the population and healthcare setting 
in which the test is intended to be used, and its 
potential downstream consequences in clinical prac-
tice. No new test should be subjected to tedious 
evaluation if the test is unlikely to result in improved 
clinical actions or additional measurable outcomes. 
Decision analytic modelling could be a cost-saving 
approach for assessing the potential clinical utility of 
the new biomarker in various practical scenarios. 
 Phase III: Analytic validity of new biomarker 
 Only if modelling confi rms potential clinical utility it 
is worth moving to the next phases of establishing 
clinical and analytic performance goals. Analytic 
validity studies for e.g. technical sensitivity, specifi c-
ity, imprecision and trueness should be performed, 
quality control procedures worked out and analytical 
characteristics improved, if clinical performance 
goals justify such needs. 
 Phase IV: Clinical research into the validity of tests 
(effi cacy study) 
 Clinical validity of a biomarker defi nes its ability 
to detect or predict a disorder or a response to inter-
ventions. Common questions can be: In patients 
suspected of having the target condition, will the test 
distinguish those with and without the disorder? 
This question is usually investigated in diagnostic 
accuracy studies in a representative spectrum of 
patients, in order to obtain the clinical sensitivity and 
specifi city of the test. It is important to emphasize 
that analytic and clinical validity studies are not suf-
fi cient to justify recommendations for the clinical use 
of new biomarkers. Therefore evaluation should 
move to the next stage. 
 Phase V: Clinical application/utility of tests 
(effectiveness study) 
 Clinical utility of a test relates to the balance between 
benefi ts and harms associated with the use of the 
biomarker: Do patients who undergo the test fare 
better, in terms of health outcomes, than those who 
do not? The most suitable study design for this type 
of question is a randomized controlled trial (RCT) 
or a systematic review or meta-analysis of multiple 
RCTs. 
 Phase VI: Impact of testing in practice 
(effi ciency study) 
 In this phase the ethical, legal, fi nancial or social 
implications of testing are investigated. This is best 
explored by health technology assessment and when 
guideline teams formulate recommendations. 
 Guideline developers should be particularly 
concerned and familiar with processes from Phase 
IV onwards when making judgments about recom-
mending the use of new biomarkers. The subsequent 
chapters describe key principles and processes 
of guideline development and will point to special 
areas of concern related to the development and 
























Figure 1. Phases of biomarker evaluation .
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 Principles and problems of guideline 
development 
 Clinical practice guidelines (CPG) are systematically 
developed statements providing recommendations 
about the care of specifi c diseases [2]. Good CPGs 
should be [3,4]: 
–  outcome oriented 
 – internally valid  – i.e. based on high quality 
research evidence or on formal consensus when 
evidence is confl icting or lacking 
 – reliable  – i.e. developed in an explicit, transparent 
and reproducible manner free from commercial 
infl uence or bias 
 – multidisciplinary 
 – externally valid  – i.e. clinically applicable 
 – fl exible  – i.e. adaptable to various clinical cir-
cumstances and patient preferences 
 – clear  – i.e. specifi c and readily understood by 
users 
 – regularly reviewed and updated 
 – appropriately disseminated and implemented 
 – cost-effective and 
 – amenable to measurement of their impact in 
clinical practice. 
 Before describing the ideal processes and methods of 
guideline development, the below fundamental ques-
tions need to be answered by also refl ecting on the 
current state-of-the-art: 
 – Do current guideline development methods 
work? 
 – Does guideline quality matter? 
 – Do we need guidelines at all? 
 – Do we need so many CPGs for the same 
condition? 
 – Do we need separate CPGs for covering different 
aspects of care (e.g. screening, diagnosis, treat-
ment, monitoring) of a clinical condition? 
 Do current guideline development methods 
work? 
 Critical appraisal of the methodology of CPGs by the 
AGREE Instrument [5] has shown that CPGs, often 
issued by prestigious authorities, lack the above listed 
desirable attributes in many medical fi elds [5,6]. Our 
review of 712 CPGs [6] along with a more recent 
systematic review of 626 CPGs published between 
2003 and 2008 [7, personal communication] showed 
(Table I) that in most guidelines the scope and 
purpose of recommendations (Domain 1 see Table 
I) are clearly defi ned and guidance is given in a clear 
format (Domain 4). There are signifi cant shortcom-
ings, however, in the multidisciplinary composition 
of guideline teams and involvement of patients in 
formulating recommendations (Domain 2). It has 
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could grossly infl uence the focus of guidelines and 
could enhance the interests of certain specialties, or 
governmental agencies or industry [8] as opposed to 
the interests and preferences of patients in decisions 
about their care. 
 The scores in these critical assessments were also 
low for the rigour (or reporting) of an evidence-based 
CPG methodology (Domain 3). There is particular 
concern about the quality and reliability of diagnostic 
recommendations in CPGs [9], as most recommen-
dations are based on poor quality research and there-
fore there is over-reliance on expert opinion [10]. 
Making recommendations requires subjective judg-
ments which are often dominated by some individual 
experts and their experience, rather than objective 
information gathered and evaluated systematically 
from the medical literature. Guidelines often fail 
the criteria of editorial independence, i.e. reporting 
on funding and potential confl icts of interest (Domain 
6). Furthermore, both reviews in Table II found 
that most recommendations lack external validity, 
i.e. applicability in practice (Domain 5), have a one-
size-fi ts-all mentality and rarely build fl exibility or 
contextualization into the recommendations or allow 
for individualization of care. 
 There are a number of other practical problems 
with CPGs [8]. More extensive CPGs tend to be 
more meticulous in their methodology and more 
likely to be evidence-based [9], however, they are not 
necessarily the most specifi c and practice-based as 
well [11]. So, does guideline quality matter in prac-
tice? Is there any relationship between guideline qual-
ity and content, or compliance with its use in clinical 
practice? Does guideline methodological quality 
impact on clinical outcomes? We provide further 
insight into these relationships below [6]. 
 Does guideline methodological quality matter 
in practice? 
 Critical appraisal by the AGREE Instrument is based 
on the theoretical assumption that poor methods 
potentially refl ect biased or invalid results. Thus 
AGREE provides only an assessment of the predicted 
validity of a guideline, and the likelihood that it will 
achieve its intended outcome, but it does not assess 
the impact of a guideline on any outcomes. Whilst a 
number of studies confi rm this assumption in the 
literature [12,13], other studies found no straightfor-
ward correlation between CPG quality and validity 
of content when comparing specifi c recommenda-
tions to available systematic reviews on the actual 
guideline topic [14,15]. Few studies investigated 
whether there is a relationship between guideline 
quality and their impact on practice patterns, health 
outcomes and healthcare costs. From our point of 
view it is also noteworthy that CPGs of poor meth-
odological quality on benign prostate hyperplasia and 
lower urinary tract symptoms recommended more 
diagnostic tests than those of better quality [16]. 
 Few studies investigated the correlation between 
guideline attributes and the use of CPGs in practice. 
Non-specifi c recommendations resulted in a higher 
frequency of inappropriate testing behaviour in low 
back pain syndrome than specifi c and clearly pre-
sented ones [11]. Controversial versus non controversial 
recommendations were followed in 35% and 68%, 
respectively. Vague recommendations that demanded 
a change in existing practice were followed in 44% 
and those that did not in 67%. Evidence-based rec-
ommendations were used more than non-evidence-
based ones in 71% versus 57%, respectively [3]. 
These studies highlight the importance of external 
validity, i.e. applicability of recommendations in adher-
ing to guidelines. Many guidelines are too often  “ lost 
in translation ” [17]. Therefore guideline development 
teams should pay more attention to the specifi c attri-
butes of CPGs that determine their use in practice. 
 In order to get research into practice more effec-
tively, we need to move from  “ science-driven ” guideline 
programs towards scientifi cally based but  “ customer-
driven ” approaches [17]. Guideline developers should 
provide unambiguous and clear statements, decision 
support tools, patient education materials and practical 
measurement tools with their guidelines if they wish to 
achieve that their recommendations have any measur-
able impact in clinical practice. 
 Do we need guidelines at all? 
 It is commonly accepted that guidance is universally 
needed to aid physicians in harmonizing the 
approaches and standards of care and in synthesizing 
the body of often contradicting research fi ndings. It 
is also a growing expectation that CPGs are based 
on the best available research evidence preferably 
coming from systematic reviews and meta-analyses 
addressing well focused questions related to critical 
aspects of patients care. So one may argue whether 
we need guidelines at all, or would it be better to 
have high quality trials or systematic reviews or evi-
dence summaries in form of well structured, quality 
rated evidence-tables that would provide a universal 
answer to clinically important questions? It is a 
particularly important notion as it has been demon-
strated that the quality of systematic reviews and 
meta-analyses prepared for formulating recommen-
dations, is often poor, and guideline developers do 
not assess the quality of the underlying evidence in 
a systematic process [18]. It has also been shown that 
systematic reviews, conducted solely for the purposes 
of guidelines or economic analyses, especially in the 
fi eld of diagnostics, are of poorer quality than single 
overviews performed by experts trained in review 
techniques and evidence-based medicine [19]. 
The current state-of-the-art therefore indicates that 
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probably we should concentrate our efforts and 
resources on producing more high quality research 
evidence, and less low quality guidelines. 
 Do we need so many guidelines for the same 
condition? 
 There is a plethora of CPGs for the management of 
many conditions, freely available on the World Wide 
Web [20,21,22]. There are 2442 CPGs currently 
available in the National Guideline Clearinghouse 
[20] with an additional 366 CPGs being under devel-
opment. On diabetes mellitus, there are 135 CPGs 
on [20] alone. Thus for the practicing physician it is 
often diffi cult to know which guideline to choose and 
use in everyday practice. 
 A number of CPGs sometimes provide contradict-
ing recommendations for the same condition. This is 
partly understandable as guidelines are developed in 
many countries where the local organizational, societal 
and cultural circumstances and the availability of 
resources may justify variations in the interpretation 
and application of evidence. Other valid reasons 
include differences in clinical questions, patient 
subgroups, time-span of retrieved literature, and 
judgments about the local relevance of research, and 
costs [23]. However, these differing or contradicting 
interpretations are often due to the lack of a system-
atic evidence retrieval and critical appraisal approach, 
failure to consider outcomes that are important to 
patients and to the dominance of certain personalities 
and their biased opinions or beliefs when recommen-
dations are formulated. Therefore a more transparent 
process for CPG development would be needed 
where reasons for deviations from the research 
evidence are clearly explained and justifi ed. 
 Do we need separate guidelines for covering 
different aspects of care of a clinical 
condition? 
 The reason for the high number of CPGs is also that 
in many situations there are parallel developments of 
recommendations for various aspects of care by rel-
evant professional bodies. This might be seen as a 
pragmatic approach, as this way, for example diagnos-
tic guidelines, can better focus on specifi c diagnostic 
problems. CPGs are often huge documents of several 
hundred pages which hardly anyone reads, let alone 
uses in practice. Others argue that specifi c recommen-
dations developed in isolation by subspecialty experts 
rarely reach their target audience as they are not part 
of a larger leading clinical guideline. Whilst both argu-
ments are valid, our view is that subspecialty organiza-
tions often develop more focused and specifi c 
recommendations. To achieve their aims, however, 
these also need to be conceived in a multidisciplinary 
process or at least consulted with and endorsed by 
relevant clinical or patient organizations who are the 
primary target groups of the recommendations. Such 
subspecialty recommendations can either be adopted 
and cross-referenced by clinical organizations or 
incorporated into the relevant larger CPG without 
unnecessarily duplicating the efforts of guideline 
teams. 
 Processes of guideline development 
 How can we change the current situation and how 
CPGs should be developed, particularly when making 
recommendations about the use of new biomarkers? 
Guidelines can be adopted or adapted or developed 
 de novo . Adoption of guidelines means that recom-
mendations are used in the same format as issued by 
the authority responsible for releasing the CPG. 
Guideline adaptation refers to the modifi cation of a 
CPG produced for use in one cultural and organiza-
tional context to be applied in a different setting [24]. 
Adaptation can be used as an alternative to  de novo 
guideline development or for customizing an existing 
guideline to suit the local context. CPG adaptation 
is carried out in three key phases as detailed in 
Figure 2. Guideline adaptation is particularly useful 
in low resource countries as they provide a cost-
conscious solution to standardizing practice. 
 The fl owchart of developing new CPGs is shown 
in Figure 3. Once the remit and clinical questions of 
the CPG are defi ned the critical steps in the process 
are how systematically the underlying research evi-
dence is collected, selected, appraised and synthe-
sized to give unbiased information which the CPG 
team can interpret further. This is probably the most 
time-consuming element of CPG development which 
needs special skills and training. Often busy clinicians 
or laboratory professionals neither have the time, nor 
the necessary training to carry out a thorough inves-
tigation. It is also unrealistic that all recommenda-
tions in a CPG would be based on systematic reviews 
of the relevant literature. Therefore CPG teams should 
prioritize their key questions and cover those with 
more meticulous reviews that are likely to infl uence 
patient relevant outcomes. 
 In good guidelines the overall quality or strength 
of the evidence and the strength of recommendations 
are graded separately. The quality of evidence indi-
cates the degree of confi dence that the evidence is 
adequate to support recommendations. This can be 
judged by considering several factors: 1/ the level of 
evidence of individual studies, which refers to the 
detailed study methods and the quality of their exe-
cution; 2/ the precision (confi dence interval) of effect 
estimates; 3/ the consistency of results across various 
studies; 4/ the directness of the evidence, i.e. the 
extent to which the study ’ s patients, interventions, 
and outcomes are similar to those in practice (NB: 
114  A. R. Horvath et al. 
diagnostic studies using surrogate outcomes usually 
provide indirect evidence). These pieces of informa-
tion can be gathered from phase IV and V biomarker 
evaluation studies (Figure 1). 
 One of the diffi culties of this process is that most 
grading systems were developed for therapeutic 
interventions or test-treatment combinations that 
cannot be uniformly applied to all types of diagnos-
tic questions in CPGs. It is often not recognized that 
different types of clinical questions can be addressed 
by differing study designs, and not all questions are 
answerable by a randomized controlled trial that 
currently represents the highest level of evidence of 
most grading schemes. In laboratory medicine, most 
recommendations are related to the clinical perfor-
mance of tests for diagnosing, monitoring or prog-
nosing conditions, or to some practical issues 
regarding the pre-analytical (e.g. requesting, taking 
and transporting or storing of specimens to the lab-
oratory) and post-analytical phases (e.g. interpreting 
or calculating test results) of the diagnostic process. 
Some guideline manuals acknowledge these diffi culties 
and provide special appraisal checklists for rating the 
quality of diagnostic studies [25]. 
 Beyond the body of evidence, guideline developers 
need to give due consideration to other practical 
aspects as well: the balance between benefi ts and 
harms; the transferability of the evidence to the given 
population, condition, or outcomes (i.e. Phase V); 
the preferences of the patient; impact on health care 
organization and costs (i.e. Phase VI) [26]. These 
value judgments help in grading the strength of 
recommendations, which indicates the extent to 
which one can be confi dent that adherence to the 
recommendation will do more good than harm [26]. 
The process of considered judgment introduces sub-
jectivity into the CPG development process. To avoid 
the dominance of opinion leaders, this phase should 
be carried out by an unbiased expert team in a trans-
parent and well-documented process. 
 What can a guideline development team do if, in 
spite of all efforts, the literature search has found no 
evidence that addresses a key review question or if 
the quality of the clinical evidence found is poor 
or confl icting, or not directly applicable to the popu-
lation covered by the guideline? In these situations, 
which are not uncommon when diagnostic recom-
mendations are made, the CPG team should explic-
itly state the root of the problem and should consider 
using a robust formal consensus method to identify 
current best practices. Other, lower priority ques-
tions could be also addressed in a less formal way 
and turned into  “ good practice point ” recommenda-
tions mostly driven by expert consensus and profes-
sional experience and agreement, or widely accepted 
standards of best practice [25]. This category mostly 
applies to technical (e.g. pre-analytical, analytical, 
post-analytical), organizational, economic or quality 
management aspects of laboratory practice where the 
question does not directly address health-related out-
comes of care. In these cases recommendations are 
often based on observational studies or empirical 
data, audit reports, case series or case studies, non-
systematic reviews, guidance or technical documents, 
personal opinions, expert consensus or position 
statements, usual practice, quality requirements and 
standards set by professional or legislative authorities 
or accreditation bodies. 
 However, care should be exercised with over-
interpreting the importance of clinical experience, as 
it was shown with cholesterol testing that the more 
clinical experts were involved in the CPG develop-
ment process, the less recommendations refl ected 
the best available research evidence [27]. It is 
common knowledge that when doctors ’ beliefs are 
confronted with the underlying evidence, the latter 
is usually over-ruled by expert opinion and experi-
ence, and guideline development is not immune to 
this attitude either. Therefore, any deviation from the 
evidence, due to the differing views of expert 
consensus, should be documented and the process 
and rationale made transparent for the users of 
recommendations. 
 Guidelines, issued to give advice on patient 
management, are supposed to be the most highly 
ranked and infl uential publications. Irrespective of 
their high status, CPGs are not always subjected to 
independent external peer review. Whilst the rigorous 
processes of scientifi c publications can be bypassed, 
their consequences cannot [28], therefore we advise 
Define topic, scope and remit of guideline
Formulate key questions
Convene a multidisciplinary guideline group
Identify and select the evidence
Review and synthesise the evidence
Formulate recommendations based on the 
body of evidence and considered judgment 
of the guideline panel
Prepare consultation draft
Consultation and peer review
Prepare final draft
Disseminate and implement
Evaluate and revise  
Figure 2. The process of guideline adaptation [24]. 
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It is vital that such shortcomings are overcome to 
satisfactorily translate biomarker research into 
practical, fi t-for-purpose recommendations e.g. by 
formulating methodological and reporting standards 
and agreeing on a unifi ed grading system. 
 These tools, together with higher quality Phase 
I-VI research studies might also help in improving 
the validity, reliability, fl exibility, clarity, transparency 
and other important attributes of good diagnostic 
guidelines related to the use of newly emerging 
biomarkers. 
 Although common sense dictates that rigorously 
developed CPGs, based on high quality translational 
research evidence, are more likely to improve clinically 
important outcomes, it remains to be seen whether 
this is the case. Until such research data and guide-
lines become available, CPGs should be critically 
evaluated not only for methodology but also for 
validity of their content before changing clinical 
practice. Translational research needs to be a two-
way and reciprocal process. Feed-back on the clinical 
that all CPGs are carefully scrutinized both for 
methodological and content validity before they are 
adopted, adapted and used in clinical practice. 
 Conclusions 
 The ultimate aim of biomarker development is that new 
diagnostic technologies improve disease management 
and clinical effectiveness of care and patient-centred 
outcomes. To support faster diffusion and rational 
use of new biomarkers of proven effectiveness and 
effi ciency, a multidisciplinary, more responsive and 
proportionate risk assessment during pre-market 
approval of new tests is needed. Clinical practice 
guidelines are developed to close the gap between 
research and practice, but the appearance of guide-
lines created a new gap between their development 
and use in practice. 
 Often current diagnostic guidelines fail their pur-
pose due to defi ciency in formulation, methodological 
rigour and transparency in the development process. 
Step 1. Establish an organizing committee 
Step 2. Select a guideline topic 
Step 3. Check whether adaptation is feasible
Step 4. Identify necessary resources and skills 
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Figure 3. The process of de novo guideline development. 
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